Navigation Links
Hooper Holmes Names Roy Bubbs President and CEO, Benjamin Currier Continues as Chairman
Date:4/10/2008

BASKING RIDGE, N.J., April 10 /PRNewswire-FirstCall/ -- Hooper Holmes (Amex: HH) today announced that Roy H. Bubbs has been appointed President and Chief Executive Officer and that Benjamin A. Currier will continue as Chairman of the Board of Directors. Mr. Bubbs, who has been a member of the Board since May 30, 2007, had been named to the position of President and CEO on an interim basis on February 6, 2008.

John W. Remshard, who had previously been named Chairman-Elect, continues as Chairman of the Audit Committee and member of the Governance/Nominating Committee of the Board of Directors. These roles allow him to make the greatest contribution to the Board through his extensive financial background, reflecting today's challenging economic climate.

Mr. Currier has joined the committee of Directors exploring the Company's strategic alternatives. Mr. Currier and Mr. Remshard's appointments are subject to their respective elections as Directors at the next Annual Meeting of shareholders.

About Hooper Holmes

Hooper Holmes is the leader in collecting personal health data and transforming it into useful information, enabling customers to take actions that manage or reduce their risks and expenses. As the leading provider of risk assessment services for the insurance industry, Hooper Holmes provides insurers with the widest range of medical exam, data collection, laboratory testing and underwriting services in the industry.

With presence in over 250 markets and a network of thousands of examiners, Hooper Holmes can arrange a medical exam anywhere in the U.S. and deliver the results to its customers. Each year we arrange more medical exams than any other company and process 3.8 million specimens in our laborator
'/>"/>

SOURCE Hooper Holmes
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Hooper Holmes Announces Fourth Quarter Earnings Release Date and Conference Call Information
2. Hooper Holmes to Provide Business Update
3. Hooper Holmes Updates Guidance
4. Hooper Holmes Marks 50,000 Health and Wellness Screenings
5. Hooper Holmes Announces Third Quarter 2007 Results
6. Hooper Holmes Appoints Leslie Hudson, PhD, to Board of Directors
7. Hooper Holmes Announces Third Quarter Earnings Release Date and Conference Call Information
8. Hooper Holmes Introduces Mature Assessment
9. Hooper Holmes to Exhibit at the 2007 Sixth Annual Association of Home Office Underwriters Conference
10. Hooper Holmes Concludes Sale of Medicals Direct
11. Hooper Holmes Launches Health & Wellness Division at 2007 Disease Management Leadership Forum and Integrated Care Summit
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:GSK Study Showed Targeted Therapy Combination Achieved 14 Month Overall Survival in Patients with Advanced Breast Cancer 2GSK Study Showed Targeted Therapy Combination Achieved 14 Month Overall Survival in Patients with Advanced Breast Cancer 3GSK Study Showed Targeted Therapy Combination Achieved 14 Month Overall Survival in Patients with Advanced Breast Cancer 4GSK Study Showed Targeted Therapy Combination Achieved 14 Month Overall Survival in Patients with Advanced Breast Cancer 5GSK Study Showed Targeted Therapy Combination Achieved 14 Month Overall Survival in Patients with Advanced Breast Cancer 6Hill-Rom Introduces Innovative Smart Bed for Medical-Surgical Settings 2Hill-Rom Introduces Innovative Smart Bed for Medical-Surgical Settings 3Hill-Rom Introduces Innovative Smart Bed for Medical-Surgical Settings 4CVS Caremark Names New Chief Human Resources Officer 2Emerson Ecologics Introduces the Emerson Quality Partner 28TM 29 Program 55830 1Emerson Ecologics Introduces the Emerson Quality Partner 28TM 29 Program 55830 2Archi Tech Closes the Gap Between Pharmaceutical Managed Care and Primary Sales with Pull Through Reporting Capabilities 55826 1Archi Tech Closes the Gap Between Pharmaceutical Managed Care and Primary Sales with Pull Through Reporting Capabilities 55826 2NOVAVAX Announces Positive Results for the Second Phase II Clinical Trial of its Trivalent Seasonal Influenza Virus like Particle 28VLP 29 Vaccine Ca 13759 1NOVAVAX Announces Positive Results for the Second Phase II Clinical Trial of its Trivalent Seasonal Influenza Virus like Particle 28VLP 29 Vaccine Ca 13759 2NOVAVAX Announces Positive Results for the Second Phase II Clinical Trial of its Trivalent Seasonal Influenza Virus like Particle 28VLP 29 Vaccine Ca 13759 3NOVAVAX Announces Positive Results for the Second Phase II Clinical Trial of its Trivalent Seasonal Influenza Virus like Particle 28VLP 29 Vaccine Ca 13759 4NOVAVAX Announces Positive Results for the Second Phase II Clinical Trial of its Trivalent Seasonal Influenza Virus like Particle 28VLP 29 Vaccine Ca 13759 5